Insiders trading at Generation Bio Co
Over the last 4 years, insiders at Generation Bio Co have traded over $37,722,950 worth of Generation Bio Co stock and bought 4,282,125 units worth $70,408,633 . The most active insiders traders include Jason P Rhodes, Biomedical Innovation Maste... и Public Equities, L.P.Minne .... On average, Generation Bio Co executives and independent directors trade stock every 11 days with the average trade being worth of $116,471. The most recent stock trade was executed by Yalonda Howze on 15 July 2024, trading 3,347 units of GBIO stock currently worth $8,167.
What does Generation Bio Co do?
Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
What does Generation Bio Co's logo look like?
Generation Bio Co executives and stock owners
Generation Bio Co executives and other stock owners filed with the SEC include:
-
Dr. Cameron Geoffrey McDonough,
Pres, CEO, Sec. & Director -
Dr. Tracy Zimmermann Ph.D.,
Chief Devel. Officer -
Dr. Matthew Norkunas M.B.A., M.D.,
Chief Financial Officer -
Antoinette Paone M.B.A., M.S.,
Sr. VP & Head of Regulatory Affairs and Quality -
Dr. Douglas Kerr M.B.A., M.D., Ph.D.,
Chief Medical Officer -
Sara Den Besten,
Chief People Officer -
Phillip Samayoa Ph.D.,
Sr. VP & Head of Corp. Devel. -
Dr. Jennifer Elliott Esq., J.D., Ph.D.,
Chief Legal Officer -
Dr. Matthew Stanton Ph.D.,
Chief Scientific Officer -
Dr. Robert Kotin Ph.D.,
Co-Founder & Advisor -
Ronald Harold Wilfred Cooper,
-
Venture Fund X, L.P.Atlas V...,
-
Capital, Llc Casdin Eli Casdin,
-
Biomedical Innovation Maste...,
10% owner -
Public Equities, L.P.Minne ...,
-
Venture Fund X, L.P. Atlas,
10% owner -
Gustav Christensen,
-
Jeffrey M Jonas,
-
James E Deerfield Mgmt L.P....,
-
Dannielle Appelhans,
-
Venture Fund X, L.P.Atlas V...,
-
Matthew Norkunas,
CHIEF FINANCIAL OFFICER -
Mark D. Angelino,
CHIEF OPERATING OFFICER -
Matthew Stanton,
CHIEF SCIENTIFIC OFFICER -
Geoff Mcdonough,
PRESIDENT AND CEO -
Tracy Zimmermann,
CHIEF DEVELOPMENT OFFICER -
Donald William Nicholson,
-
Charles A Jr Rowland,
-
Douglas Kerr,
CHIEF MEDICAL OFFICER -
Venture Associates X, L.P.A...,
-
Venture Associates X, L.P.A...,
-
Anthony G. Quinn,
-
Venture Associates X, L.P.A...,
-
Jason P Rhodes,
-
Catherine Stehman Breen,
-
Antoinette Paone,
CHIEF OPERATING OFFICER -
Phillip Samayoa,
CHIEF STRATEGY OFFICER -
Yalonda Howze,
CHIEF LEGAL OFFICER